Amneal Pharmaceuticals (AMRX) Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AMRX shares.
View AMRX analyst ratings or view top-rated stocks.

5 Wall Street research analysts have issued 12-month target prices for Amneal Pharmaceuticals' stock. Their AMRX share price forecasts range from $3.00 to $6.00. On average, they expect the company's share price to reach $4.60 in the next year. This suggests a possible upside of 9.0% from the stock's current price.
View analysts price targets for AMRX or view top-rated stocks among Wall Street analysts.

Amneal Pharmaceuticals' stock was trading at $1.99 at the beginning of the year. Since then, AMRX shares have increased by 112.1% and is now trading at $4.22.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, November 3rd 2023.
View our AMRX earnings forecast.

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) issued its quarterly earnings results on Friday, August, 4th. The company reported $0.16 earnings per share for the quarter, beating analysts' consensus estimates of $0.08 by $0.08. The business earned $599.05 million during the quarter, compared to analyst estimates of $562.49 million. Amneal Pharmaceuticals had a negative net margin of 0.09% and a positive trailing twelve-month return on equity of 101.26%.

Amneal Pharmaceuticals issued an update on its FY 2023 earnings guidance on Friday, August, 4th. The company provided earnings per share (EPS) guidance of $0.45-$0.55 for the period, compared to the consensus estimate of $0.47. The company issued revenue guidance of $2.30 billion-$2.40 billion, compared to the consensus revenue estimate of $2.32 billion.

23 employees have rated Amneal Pharmaceuticals Chief Executive Officer Chirag and Chintu Patel on Glassdoor.com. Chirag and Chintu Patel has an approval rating of 91% among the company's employees. This puts Chirag and Chintu Patel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Cisco Systems (CSCO), Micron Technology (MU), General Electric (GE), OPKO Health (OPK), Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV) and Bausch Health Companies (BHC).

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMRX stock can currently be purchased for approximately $4.22.

Amneal Pharmaceuticals (NYSE:AMRX) has a market capitalization of $1.29 billion and generates $2.21 billion in revenue each year. The company earns $-129,990,000.00 in net income (profit) each year or ($0.02) on an earnings per share basis.

The company employs 7,600 workers across the globe.

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The official website for the company is www.amneal.com. The company can be reached via phone at (908) 947-3120, via email at invest@amneal.com, or via fax at 908-947-3146.